Influenza vaccine - Biologic Drug Details

Summary for influenza vaccine

Tradenames:	5
High Confidence Patents:	0
Applicants:	6
BLAs:	7
Suppliers: see list	8

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for influenza vaccine Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for influenza vaccine Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Glaxosmithkline Biologicals	FLUARIX, FLUARIX QUADRIVALENT	influenza vaccine	Injection	125127		2036-05-09	DrugPatentWatch analysis and company disclosures
Glaxosmithkline Biologicals	FLUARIX, FLUARIX QUADRIVALENT	influenza vaccine	Injection	125127		2028-04-15	DrugPatentWatch analysis and company disclosures
Id Biomedical Corporation Of Quebec	FLULAVAL, FLULAVAL QUADRIVALENT	influenza vaccine	Injection	125163		2033-10-25	DrugPatentWatch analysis and company disclosures
Id Biomedical Corporation Of Quebec	FLULAVAL, FLULAVAL QUADRIVALENT	influenza vaccine	Injection	125163		2042-06-23	DrugPatentWatch analysis and company disclosures
Id Biomedical Corporation Of Quebec	FLULAVAL, FLULAVAL QUADRIVALENT	influenza vaccine	Injection	125163		2034-04-28	DrugPatentWatch analysis and company disclosures
Id Biomedical Corporation Of Quebec	FLULAVAL, FLULAVAL QUADRIVALENT	influenza vaccine	Injection	125163		2028-04-15	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for influenza vaccine Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Glaxosmithkline Biologicals	FLUARIX, FLUARIX QUADRIVALENT	influenza vaccine	Injection	125127		2036-10-12	Patent claims search
Glaxosmithkline Biologicals	FLUARIX, FLUARIX QUADRIVALENT	influenza vaccine	Injection	125127		2034-01-23	Patent claims search
Glaxosmithkline Biologicals	FLUARIX, FLUARIX QUADRIVALENT	influenza vaccine	Injection	125127		2034-09-23	Patent claims search
Glaxosmithkline Biologicals	FLUARIX, FLUARIX QUADRIVALENT	influenza vaccine	Injection	125127		2032-10-01	Patent claims search
Glaxosmithkline Biologicals	FLUARIX, FLUARIX QUADRIVALENT	influenza vaccine	Injection	125127		2035-08-03	Patent claims search
Glaxosmithkline Biologicals	FLUARIX, FLUARIX QUADRIVALENT	influenza vaccine	Injection	125127		2035-08-18	Patent claims search

International Patents for influenza vaccine

Country	Patent Number	Estimated Expiration
Japan	2009520771
Portugal	3067064
Norway	20190104
China	101460193
Mexico	337932
European Patent Office	2364721

Supplementary Protection Certificates for influenza vaccine

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
122020000047	Germany		PRODUCT NAME: INFLUENZAVIRUS-HAEMAGGLUTININ, INAKTIVIERT, DER FOLGENDEN STAEMME HERGESTELLT IN ZELLKULTUR: B/XXXXX - AEHNLICHER STAMM B/XXXXX - AEHNLICHER STAMM; REGISTRATION NO/DATE: EU/1/18/1326 20181212
122024000055	Germany		PRODUCT NAME: INFLUENZA-A-VIRUS-H5-HAEMAGGLUTININ-OBERFLAECHENANTIGEN, INAKTIVIERT, HERGESTELLT IN ZELLKULTUREN; REGISTRATION NO/DATE: EU/1/24/1806 20240419
C20240033	Finland
SPC/GB20/045	United Kingdom		PRODUCT NAME: INFLUENZA VIRUS HAEMAGGLUTININ, INACTIVATED, OF THE FOLLOWING STRAINS PREPARED IN CELL CULTURES: B/XXXXX-LIKE STRAIN B/XXXXX-LIKE STRAIN; REGISTERED: UK EU/1/18/1326/001(NI) 20181212; UK PLGB 47991/0003 20181212
CA 2024 00037	Denmark		PRODUCT NAME: INFLUENZA A VIRUS H5 HAEMAGGLUTININ OVERFLADEANTIGEN, INAKTIVERET, FREMSTILLET I CELLEKULTURER; REG. NO/DATE: EU/1/24/1806, EU/1/24/1807 20240422

Influenza vaccine Market Analysis and Financial Projection

Last updated: February 15, 2026

Overview of Influenza Vaccine Biologics Market

The influenza vaccine market is robust, driven by seasonal demand, pandemic preparedness, and evolving vaccine technologies. In 2022, global influenza vaccine sales reached approximately $4.7 billion, with projections indicating a compound annual growth rate (CAGR) of 7% through 2027, reaching around $7 billion.[1]

Key Market Drivers

Seasonal and Pandemic Preparedness

Annual vaccination campaigns target high-risk groups, maintaining steady demand. The COVID-19 pandemic heightened awareness around vaccine development, boosting investments in influenza vaccine innovations.

Technological Innovation

Advances include egg-free production, recombinant DNA technology, and mRNA platforms. These improvements aim to increase efficacy, reduce production time, and enhance responsiveness to emerging strains.

Regulatory Environment

Regulatory agencies like the FDA and EMA foster innovation via accelerated approval pathways, especially during health emergencies. Expanded licensing for universal influenza vaccines is underway but remains limited in commercial scope.

Market Segments and Products

Types of Influenza Vaccines

Segment	Description	2022 Market Share	Notes
Traditional (Egg-based)	Inactivated vaccines produced in eggs	~60%	Most prevalent; long-established technology
Recombinant	Uses recombinant DNA technology; egg-free	~15%	Growing due to safety and scalability benefits
mRNA-Based	Lipid nanoparticle-encapsulated mRNA vaccines	Emerging	Clinical trials; potential for rapid strain updates
Live Attenuated	Weakened virus vaccines administered intranasally	~10%	Used mainly for children; declining due to efficacy concerns

Key Players

• Sanofi Pasteur
• Seqirus (a CSL company)
• AstraZeneca (through its vaccine division)
• GlaxoSmithKline (GSK)
• Emerging biotech firms focusing on universal vaccines

Financial Trajectory

Revenue Trends

Sanofi Pasteur is the market leader, with segment revenues of approximately $1.5 billion in 2022.[2] Seqirus follows with an estimated $1.2 billion. The combined top five players capture over 75% of the global market.

R&D Investment

Biotech companies and big pharmas allocate substantial resources to vaccine innovation. In 2022, total R&D expenditure on influenza biologics reached $1.2 billion, a 12% year-over-year increase.[3] Investments focus on next-generation vaccines aimed at broader and longer-lasting immunity.

Pricing and Reimbursement

Pricing varies widely by region, with developed markets averaging $20-$50 per dose. Reimbursement policies influence market accessibility, especially in the US and Europe, where government programs and private insurers utilize cost-benefit analyses to set vaccination coverage levels.

Challenges Impacting Market Dynamics

Strain Variability and Vaccine Effectiveness

Strain matching remains a challenge, with vaccine effectiveness varying annually from 40% to 60%.[4] This variability impacts demand and encourages innovation towards universal vaccines.

Production Capabilities and Scalability

Egg-based manufacturing faces limitations in scalability and speed, especially during pandemics. mRNA and recombinant platforms offer scalable alternatives but face regulatory hurdles.

Public Perception and Vaccine Acceptance

Vaccine hesitancy influences uptake. Efforts to improve public trust focus on efficacy transparency and addressing safety concerns.

Market Outlook and Future Trends

Universal Influenza Vaccines

Research focuses on vaccines targeting conserved viral regions for broad, long-lasting immunity. Several candidates are in late-stage clinical trials, with potential market entry within five years.

mRNA Technology Expansion

mRNA platforms, proven effective during COVID-19, are being adapted for influenza. Trials are underway, and commercialization could commence by 2025.

Digital and Personalized Vaccines

Personalized approaches based on viral genomics are under exploration, potentially allowing for strain-specific formulations at increased speed.

Regulatory and Policy Evolution

Regulatory pathways for novel platforms will shape market entry timelines. Governments are increasing funding for universal vaccines and pandemic preparedness.

Key Takeaways

• The influenza vaccine biologics market stands at approximately $4.7 billion in 2022, with steady growth driven by technological advances and global health policies.
• Egg-based vaccines dominate sales but face competition from recombinant and mRNA platforms, which promise scalability and faster response times.
• Investment in vaccine R&D exceeds $1.2 billion annually, targeting broad-spectrum and universal options.
• Challenges include strain variability, manufacturing capacity, and vaccine hesitancy, influencing demand and strategic planning.
• Future growth depends on the success of universal vaccines and mRNA platforms, alongside regulatory adaptations.

FAQs

1. What factors most influence the growth of the influenza vaccine market?
Technological innovation, pandemic preparedness, regulatory support, and public vaccination acceptance drive growth.

2. What are the main technological shifts in influenza vaccines?
Transition from egg-based to recombinant and mRNA platforms, aiming for broader, longer-lasting immunity and quick strain updates.

3. When can universal influenza vaccines reach commercial markets?
Candidates are in late-stage clinical trials; commercialization could occur within five years, contingent on regulatory approvals.

4. How does vaccine efficacy variability impact market dynamics?
It enhances demand for universal vaccines and newer platforms with higher and more consistent efficacy profiles.

5. What role does government policy play in this market?
Policies influence reimbursement, funding for R&D, and pandemic preparedness strategies, shaping product development and deployment strategies.

---

References

[1] MarketWatch, "Global Influenza Vaccine Market Size, Share & Trends," 2022.
[2] Sanofi Annual Report 2022.
[3] IMARC Group, "Influenza Vaccine Market Report," 2023.
[4] CDC, "Vaccine Effectiveness - Annual Review," 2022.